FDA approves Vemurafenib for patients with Erdheim-Chester Disease

November 6, 2017
The U.S. Nourishment and Drug Administration today expanded the endorsement of Zelboraf (vemurafenib) to incorporate the treatment of certain grown-up patients with Erdheim-Chester Disease (ECD), an uncommon malignancy of... Read more »